Loading...
•
Mar 31, 2025
OptimizeRx Q1 2025 Earnings Report
OptimizeRx reported increased revenue and narrowed net loss for Q1 2025.
Key Takeaways
OptimizeRx delivered top-line growth and improved bottom-line performance in Q1 2025, supported by enhanced gross profit and positive non-GAAP earnings, alongside raised full-year guidance.
Revenue rose to $21,928,000 from $19,690,000 year-over-year
GAAP net loss narrowed to $2,199,000 from $6,899,000
Non-GAAP net income reached $1,539,000 compared to a loss in Q1 2024
Cash and short-term investments increased to $16,573,000
Forward Guidance
OptimizeRx increased its FY2025 revenue and adjusted EBITDA guidance following a solid Q1 marked by strong momentum and strategic shifts.
Positive Outlook
- Revenue guidance raised to $101–$106 million
- Adjusted EBITDA guidance lifted to $13–$15 million
- Over 5% of expected 2025 sales converted to subscriptions
- Strong start positions company well for second half of 2025
- Operational leverage continues to improve
Challenges Ahead
- GAAP profitability remains negative
- Operating expenses still outpace gross profit
- Interest expenses exceeded $1.2 million
- One-time charges impacted results (e.g. activist and CEO search fees)
- Revenue share payable declined, possibly affecting future cash flows
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...